Related Experiment Videos

ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic

Philip A Poole-Wilson1

  • 1Division of Cardiac Medicine, Imperial College Faculty of Medicine, National Heart and Lung Institute, London, United Kingdom. p.poole-wilson@ic.ac.uk

The Medical Clinics of North America
|April 16, 2003
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors significantly improve outcomes for patients with heart failure and reduced ejection fraction. Current guidelines recommend combining ACE inhibitors with diuretics, adding beta-blockers for select individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is a significant clinical challenge.
  • Angiotensin-converting enzyme (ACE) inhibitors have demonstrated substantial benefits in managing HFrEF.

Purpose of the Study:

  • To review the established benefits of ACE inhibitors in heart failure patients.
  • To discuss current treatment guidelines and the role of other pharmacotherapies.
  • To address uncertainties in specific patient subgroups and the evaluation of new therapies.

Main Methods:

  • Systematic review and synthesis of existing clinical trial data on ACE inhibitors in heart failure.
  • Analysis of current treatment recommendations and emerging therapeutic strategies.

Main Results:

  • Overwhelming evidence supports ACE inhibitors in reducing mortality, hospitalizations, and symptoms while improving exercise capacity in HFrEF.
  • Combination therapy with diuretics is standard; beta-blockers are indicated for selected patients.
  • Evidence for Angiotensin II Receptor Blockers (ARBs) is less compelling, reserved for ACE inhibitor intolerance.

Conclusions:

  • ACE inhibitors are a cornerstone therapy for heart failure with reduced ejection fraction.
  • Challenges remain in evaluating new treatments for efficacy and safety compared to existing therapies.
  • Future research may explore ACE inhibitors for primary prevention of heart failure, particularly in coronary heart disease patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...